NVAX Novavax, Inc.

1.19
+0.01  (1%)
Previous Close 1.18
Open 1.21
Price To book 0.00
Market Cap 336.29M
Shares 282,595,000
Volume 2,929,927
Short Ratio 8.63
Av. Daily Volume 6,304,530

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial initiation announced January 19, 2017. Data due by early August, 2017 (official guidance is within 90 days of May 8, 2017.
RSV F Vaccine immunogenicity trial
Respiratory Syncytial Virus (RSV) in older adults
Phase 3 initiated December 2015. Expected to take 2-4 years to complete
RSV vaccine - prepare trial
Respiratory Syncytial Virus (RSV) in healthy pregnant women - protect infants via maternal immunization
Phase 3 released September 15, 2016 did not demonstrate efficacy.
RSV vaccine - Resolve trial
Respiratory Syncytial Virus (RSV) in older adults
Phase 2 data released September 15, 2016.
RSV F Vaccine rollover trial
Respiratory Syncytial Virus (RSV) in older adults
Further Phase 2 trials planned
Seasonal Influenza Vaccine
Seasonal Flu